1. KirsnerJB. (ed.)Inflammatory Bowel Disease, 5th ed. Baltimore: Williams &Wilkins; 2000.

2. SwaroopP, PodolskyDK. Inflammatory bowel disease: Crohn's disease and ulcerative colitis. In: BopeET, KellermanRD(eds). Conn's Current Therapy 2015. Philadelphia: Elsevier Saunders; 2015: 563.

3. PodolskyDK. Inflammatory bowel disease. N Engl J Med2002;347:417. CrossRef

4. MonsenU, BrostromO, NordenvallB, et al.Prevalence of inflammatory bowel disease among relatives of patients with ulcerative colitis. Scand J Gastroenterol1987;22:214. CrossRef

5. MolodeckyNA, SoonIS, RabiDM, et al.Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology2012;142:46. CrossRef

6. NgSC, TangW, ChingJY, et al.Incidence and phenotype of inflammatory bowel disease based on results from the Asia‐pacific Crohn's and colitis epidemiology study. Gastroenterology2013;145:158. CrossRef

7. McConnellR, RosenR, LangmanM, et al.The Genetics and Epidemiology of Inflammatory Bowel Disease. New York: Karger; 1986.

8. CalkinsBM, LilienfeldAM, GarlandCF, et al.Trends in incidence rates of ulcerative colitis and Crohn's disease. Dig Dis Sci1984;29:913. CrossRef

9. SandsBE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology2004;126:1518. CrossRef

10. LangholzE, MunkholmP, DavidsenM, et al.Changes in extent of ulcerative colitis: a study on the course and prognostic factors. Scand J Gastroenterol1996;31:260. CrossRef

11. MoumB, EkbomA, VatnMH, et al.Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol1999;94:1564. CrossRef

12. FarmerM, PetrasRE, HuntLE, et al.The importance of diagnostic accuracy in colonic inflammatory bowel disease. Am J Gastroenterol2000;95:3184. CrossRef

13. SchumacherG, SandstedtB, KollbergB. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Clinical findings and early diagnosis. Scand J Gastroenterol1994;29:265. CrossRef

14. RaoSS, ReadNW, DavisonPA, et al.Anorectal sensitivity and responses to rectal distention in patients with ulcerative colitis. Gastroenterology1987;93:1270.

15. FarmerRG, EasleyKA, RankinGB. Clinical patterns, natural history, and progression of ulcerative colitis. A long‐term follow‐up of 1116 patients. Dig Dis Sci1993;38:1137. CrossRef

16. RaoSS, HoldsworthCD, ReadNW. Symptoms and stool patterns in patients with ulcerative colitis. Gut1988;29:342. CrossRef

17. GanSI, BeckPL. A new look at toxic megacolon: an update and review of incidence, etiology, pathogenesis, and management. Am J Gastroenterol2003;98:2363. CrossRef

18. TrueloveSC, WittsLJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J1955;2:1041. CrossRef

19. CarterMJ, LoboAJ, TravisSP. Guidelines for the management of inflammatory bowel disease in adults. Gut2004;53(Suppl 5):V1. CrossRef

20. KornbluthA, SacharDB. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol2004;99:1371. CrossRef

21. SandsBE, AbreuMT, FerryGD, et al.Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis2005;11(Suppl 1):S22. CrossRef

22. VindI, RiisL, JessT, et al.Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003–2005: a population‐based study from the Danish Crohn colitis database. Am J Gastroenterol2006;101:1274. CrossRef

23. LangholzE, MunkholmP, DavidsenM, et al.Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology1994;107:3.

24. FaubionWAJr, LoftusEVJr, HarmsenWS, et al.The natural history of corticosteroid therapy for inflammatory bowel disease: a population‐based study. Gastroenterology2001;121:255. CrossRef

25. CardT, HubbardR, LoganRF. Mortality in inflammatory bowel disease: a population‐based cohort study. Gastroenterology2003;125:1583. CrossRef

26. JessT, LoftusEVJr, HarmsenWS, et al.Survival and cause specific mortality in patients with inflammatory bowel disease: a long term outcome study in Olmsted County, Minnesota, 1940–2004. Gut2006;55:1248. CrossRef

27. EdwardsFC, TrueloveSC. The course and prognosis of ulcerative colitis. Gut1963;4:299. CrossRef

28. BradesiS, McRobertsJA, AntonPA, et al.Inflammatory bowel disease and irritable bowel syndrome: separate or unified?Curr Opin Gastroenterol2003;19:336. CrossRef

29. SuCG, JudgeTA, LichtensteinGR. Extraintestinal manifestations of inflammatory bowel disease. Gastroenterol Clin North Am2002;31:307. CrossRef

30. LanghorstJ, ElsenbruchS, MuellerT, et al.Comparison of 4 neutrophil‐derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis2005;11:1085. CrossRef

31. BunnSK, BissetWM, MainMJ, et al.Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr2001;33:14. CrossRef

32. BunnSK, BissetWM, MainMJ, et al.Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr2001;32:171. CrossRef

33. AadlandE, FagerholMK. Faecal calprotectin: a marker of inflammation throughout the intestinal tract. Eur J Gastroenterol Hepatol2002;14:823. CrossRef

34. Delgado‐ArosS, CremoniniF. Role of fecal calprotectin test in the work‐up of IBS patients. Gastroenterology2003;124:1164. CrossRef

35. TibbleJA, SigthorssonG, BridgerS, et al.Surrogate markers of intestinal inflammation are predictive of relapse in patients with inflammatory bowel disease. Gastroenterology2000;119:15. CrossRef

36. LewisJD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology2011;140:1817. CrossRef

37. KaneSV, SandbornWJ, RufoPA, et al.Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol2003;98:1309. CrossRef

38. FineKD, OgunjiF, GeorgeJ, et al.Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. Am J Gastroenterol1998;93:1300. CrossRef

39. ShanahanF. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology2001;120:622. CrossRef

40. BossuytX. Serologic markers in inflammatory bowel disease. Clin Chem2006;52:171. CrossRef

41. VasiliauskasE. Recent advances in the diagnosis and classification of inflammatory bowel disease. Curr Gastroenterol Rep2003;5:493. CrossRef

42. CohavyO, BrucknerD, GordonLK, et al.Colonic bacteria express an ulcerative colitis pANCA‐related protein epitope. Infect Immun2000;68:1542. CrossRef

43. EggenaM, CohavyO, ParseghianMH, et al.Identification of histone H1 as a cognate antigen of the ulcerative colitis‐associated marker antibody pANCA. J Autoimmun2000;14:83. CrossRef

44. VasiliauskasEA, PlevySE, LandersCJ, et al.Perinuclear antineutrophil cytoplasmic antibodies in patients with Crohn's disease define a clinical subgroup. Gastroenterology1996;110:1810. CrossRef

45. GuptaN, CohenSA, BostromAG, et al.Risk factors for initial surgery in pediatric patients with Crohn's disease. Gastroenterology2006;130:1069. CrossRef

46. Barahona‐GarridoJ, Camacho‐EscobedoJ, Garcia‐MartinezCI, et al.Antinuclear antibodies: a marker associated with steroid dependence in patients with ulcerative colitis. Inflamm Bowel Dis2009;15:1039. CrossRef

47. DubinskyMC, JohansonJF, SeidmanEG, et al.Suspected inflammatory bowel disease–the clinical and economic impact of competing diagnostic strategies. Am J Gastroenterol2002;97:2333.

48. PeetersM, JoossensS, VermeireS, et al.Diagnostic value of anti‐Saccharomyces cerevisiae and antineutrophil cytoplasmic autoantibodies in inflammatory bowel disease. Am J Gastroenterol2001;96:730. CrossRef

49. ChutkanRK, ScherlE, WayeJD. Colonoscopy in inflammatory bowel disease. Gastrointest Endosc Clin N Am2002;12:463, viii. CrossRef

50. GoldsteinN, DulaiM. Contemporary morphologic definition of backwash ileitis in ulcerative colitis and features that distinguish it from Crohn disease. Am J Clin Pathol2006;126:365. CrossRef

51. HoganWJ, HensleyGT, GeenenJE. Endoscopic evaluation of inflammatory bowel disease. Med Clin North Am1980;64:1083.

52. SutherlandLR, MartinF, GreerS, et al.5‐Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology1987;92:1894.

53. D′HaensG, GeboesK, PeetersM, et al.Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol1997;92:1275.

54. BernsteinCN, ShanahanF, WeinsteinWM. Histological patchiness and sparing of the rectum in ulcerative colitis: refuting the dogma [letter; comment]. J Clin Pathol1997;50:354. CrossRef

55. GeboesK, DalleI. Influence of treatment on morphological features of mucosal inflammation. Gut2002;50(Suppl 3):III37. CrossRef

56. AlemayehuG, JarnerotG. Colonoscopy during an attack of severe ulcerative colitis is a safe procedure and of great value in clinical decision making. Am J Gastroenterol1991;86:187.

57. CarbonnelF, GargouriD, LemannM, et al.Predictive factors of outcome of intensive intravenous treatment for attacks of ulcerative colitis. Aliment Pharmacol Ther2000;14:273. CrossRef

58. CarbonnelF, LavergneA, LemannM, et al.Colonoscopy of acute colitis. A safe and reliable tool for assessment of severity. Dig Dis Sci1994;39:1550. CrossRef

59. KishoreJ, GhoshalU, GhoshalUC, et al.Infection with cytomegalovirus in patients with inflammatory bowel disease: prevalence, clinical significance and outcome. J Med Microbiol2004;53:1155. CrossRef

60. MantzarisGJ, HatzisA, ArchavlisE, et al.The role of colonoscopy in the differential diagnosis of acute, severe hemorrhagic colitis. Endoscopy1995;27:645. CrossRef

61. TanakaM, RiddellRH, SaitoH, et al.Morphologic criteria applicable to biopsy specimens for effective distinction of inflammatory bowel disease from other forms of colitis and of Crohn's disease from ulcerative colitis. Scand J Gastroenterol1999;34:55. CrossRef

62. JenkinsD, BalsitisM, GallivanS, et al.Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol1997;50:93. CrossRef

63. SurawiczCM, BelicL. Rectal biopsy helps to distinguish acute self‐limited colitis from idiopathic inflammatory bowel disease. Gastroenterology1984;86:104.

64. JudgeTA, LewisJD, LichtensteinGR. Colonic dysplasia and cancer in inflammatory bowel disease. Gastrointest Endosc Clin N Am2002;12:495. CrossRef

65. RiddellRH, GoldmanH, RansohoffDF, et al.Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum Pathol1983;14:931. CrossRef

66. MackalskiBA, BernsteinCN. New diagnostic imaging tools for inflammatory bowel disease. Gut2006;55:733. CrossRef

67. KornbluthA, SacharDB. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol2010;105:501, quiz 524. CrossRef

68. CharronM. Technetium leukocyte imaging in inflammatory bowel disease. Curr Gastroenterol Rep1999;1:245. CrossRef

69. BruiningDH, LoftusEV. Evolving diagnostic strategies for inflammatory bowel disease. Curr Gastroenterol Rep2006;8:478. CrossRef

70. LauensteinTC, AjajW, KuehleCA. Virtual colonoscopy by MRI: state‐of‐the‐art and future directions. Gastrointest Endosc Clin N Am2005;15:797. CrossRef

71. AjajWM, LauensteinTC, PelsterG, et al.Magnetic resonance colonography for the detection of inflammatory diseases of the large bowel: quantifying the inflammatory activity. Gut2005;54:257. CrossRef

72. FiremanZ, MahajnaE, BroideE, et al.Diagnosing small bowel Crohn's disease with wireless capsule endoscopy. Gut2003;52:390. CrossRef

73. McEwenC. Arthritis accompanying ulcerative colitis. Clin Orthop Relat Res1968;57:9.

74. Fernandez‐HerlihyL. The articular manifestations of chronic ulcerative colitis; an analysis of 555 cases. N Engl J Med1959;261:259. CrossRef

75. MillerMM. Ankylosing spondylitis, Reiter's syndrome, psoriatic arthritis, and arthritis of inflammatory bowel disease. Prim Care1984;11:271.

76. OrchardT. Extraintestinal complications of inflammatory bowel disease. Curr Gastroenterol Rep2003;5:512. CrossRef

77. SandbornWJ, StensonWF, BrynskovJ, et al.Safety of celecoxib in patients with ulcerative colitis in remission: a randomized, placebo‐controlled, pilot study. Clin Gastroenterol Hepatol2006;4:203. CrossRef

78. HerfarthH, ObermeierF, AndusT, et al.Improvement of arthritis and arthralgia after treatment with infliximab (Remicade) in a German prospective, open‐label, multicenter trial in refractory Crohn's disease. Am J Gastroenterol2002;97:2688. CrossRef

79. BrewertonDA, CaffreyM, NichollsA, et al.HL‐A 27 and arthropathies associated with ulcerative colitis and psoriasis. Lancet1974;1:956. CrossRef

80. WrightV, WatkinsonG. Articular complications of ulcerative colitis. Am J Proctol1966;17:107.

81. BernsteinCN, BlanchardJF, LeslieW, et al.The incidence of fracture among patients with inflammatory bowel disease. A population‐based cohort study. Ann Intern Med2000;133:795. CrossRef

82. American Gastroenterological Association. American Gastroenterological Association Medical Postion Statement: guidelines in osteoporosis in gastrointestinal diseases. Gastroenterology2003;124:791. CrossRef

83. ScottEM, GaywoodI, ScottBB. Guidelines for osteoporosis in coeliac disease and inflammatory bowel disease. British Society of Gastroenterology. Gut2000;46(Suppl 1):i1. CrossRef

84. PardiDS, TremaineWJ, SandbornWJ, et al.Renal and urologic complications of inflammatory bowel disease. Am J Gastroenterol1998;93:504. CrossRef

85. GrossmanMS, NugentFW. Urolithiasis as a complication of chronic diarrheal disease. Am J Dig Dis1967;12:491. CrossRef

86. ThorntonJR, TeagueRH, Low‐BeerTS, et al.Pyoderma gangrenosum and ulcerative colitis. Gut1980;21:247. CrossRef

87. PerryHO. Pyoderma gangrenosum. South Med J1969;62:899. CrossRef

88. SotoLD. Diaminodiphenylsulfone and steroids in the treatment of pyoderma gangrenosum. Int J Dermatol1970;9:293. CrossRef

89. GelerntIM, KreelI. Pyoderma gangrenosum in ulcerative colitis: prevention of the gangrenous component. Mt Sinai J Med1976;43:467.

90. FriedmanS, MarionJF, ScherlE, et al.Intravenous cyclosporine in refractory pyoderma gangrenosum complicating inflammatory bowel disease. Inflamm Bowel Dis2001;7:1. CrossRef

91. BrooklynTN, DunnillMG, ShettyA, et al.Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut2006;55:505. CrossRef

92. ReichK, VenteC, NeumannC. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol1998;139:755. CrossRef

93. BaioccoPJ, GormanBD, KorelitzBI. Uveitis occurring after colectomy and ileal‐rectal sleeve anastomosis for ulcerative colitis. Dig Dis Sci1984;29:570. CrossRef

94. SuhlerEB, SmithJR, WertheimMS, et al.A prospective trial of infliximab therapy for refractory uveitis: preliminary safety and efficacy outcomes. Arch Ophthalmol2005;123:903. CrossRef

95. BernsteinCN, BlanchardJF, HoustonDS, et al.The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population‐based cohort study. Thromb Haemost2001;85:430.

96. TalbotRW, HeppellJ, DozoisRR, et al.Vascular complications of inflammatory bowel disease. Mayo Clin Proc1986;61:140. CrossRef

97. NovacekG, WeltermannA, SobalaA, et al.Inflammatory bowel disease is a risk factor for recurrent venous thromboembolism. Gastroenterology2010;139:779, 787.e1. CrossRef

98. HudsonM, ChitolieA, HuttonRA, et al.Thrombotic vascular risk factors in inflammatory bowel disease. Gut1996;38:733. CrossRef

99. LamA, BordaIT, InwoodMJ, et al.Coagulation studies in ulcerative colitis and Crohn's disease. Gastroenterology1975;68:245.

100. ChristophiC, HughesER. Hepatobiliary disorders in inflammatory bowel disease. Surg Gynecol Obstet1985;160:187.

101. MistilisSP. Pericholangitis and ulcerative colitis. I. Pathology, etiology, and pathogenesis. Ann Intern Med1965;63:1. CrossRef

102. DewMJ, ThompsonH, AllanRN. The spectrum of hepatic dysfunction in inflammatory bowel disease. Q J Med1979;48:113.

103. MistilisSP, SkyringAP, GoulstonSJ. Pericholangitis and ulcerative colitis. II. Clinical aspects. Ann Intern Med1965;63:17. CrossRef

104. ChaparroM, Trapero‐MaruganM, GuijarroM, et al.Dysplasia and colorectal cancer in a patient with ulcerative colitis and primary sclerosing cholangitis: a case report and a short review of the literature. J Crohns Colitis2013;7:e61. CrossRef

105. TabibianJH, LindorKD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol2013;7:103. CrossRef

106. TrikudanathanG, NavaneethanU, NjeiB, et al.Diagnostic yield of bile duct brushings for cholangiocarcinoma in primary sclerosing cholangitis: a systematic review and meta‐analysis. Gastrointest Endosc2014;79:783. CrossRef

107. QuigleyEM. Irritable bowel syndrome and inflammatory bowel disease: interrelated diseases?Chin J Dig Dis2005;6:122. CrossRef

108. BurgmannT, ClaraI, GraffL, et al.The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis–how much is irritable bowel syndrome?Clin Gastroenterol Hepatol2006;4:614. CrossRef

109. Fuller‐ThomsonE, SulmanJ. Depression and inflammatory bowel disease: findings from two nationally representative Canadian surveys. Inflamm Bowel Dis2006;12:697. CrossRef

110. AdebayoD, BjarnasonI. Is non‐steroidal anti‐inflammaory drug (NSAID) enteropathy clinically more important than NSAID gastropathy?Postgrad Med J2006;82:186. CrossRef

111. GrahamDY, OpekunAR, WillinghamFF, et al.Visible small‐intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol2005;3:55. CrossRef

112. ChutkanR, ToubiaN. Effect of nonsteroidal anti‐inflammatory drugs on the gastrointestinal tract: diagnosis by wireless capsule endoscopy. Gastrointest Endosc Clin N Am2004;14:67. CrossRef

113. StallmachA, CarstensO. Role of infections in the manifestation or reactivation of inflammatory bowel diseases. Inflamm Bowel Dis2002;8:213. CrossRef

114. HoentjenF, RubinDT. Infectious proctitis: when to suspect it is not inflammatory bowel disease. Dig Dis Sci2012;57:269. CrossRef

115. ChandeN, DrimanDK, ReynoldsRP. Collagenous colitis and lymphocytic colitis: patient characteristics and clinical presentation. Scand J Gastroenterol2005;40:343. CrossRef

116. LazenbyAJ. Collagenous and lymphocytic colitis. Semin Diagn Pathol2005;22:295. CrossRef

117. LiszkaL, WoszczykD, PajakJ. Histopathological diagnosis of microscopic colitis. J Gastroenterol Hepatol2006;21:792. CrossRef

118. PeppercornMA. The overlap of inflammatory bowel disease and diverticular disease. J Clin Gastroenterol2004;38:S8. CrossRef

119. HarpazN, SacharDB. Segmental colitis associated with diverticular disease and other IBD look‐alikes. J Clin Gastroenterol2006;40:S132. CrossRef

120. LudemanL, ShepherdNA. What is diverticular colitis?Pathology2002;34:568. CrossRef

121. EggenbergerJC, FaridA. Diversion colitis. Curr Treat Options Gastroenterol.2001;4:255. CrossRef

122. ShibataC, FunayamaY, FukushimaK, et al.Factors affecting the bowel function after proctocolectomy and ileal J pouch‐anal anastomosis for ulcerative colitis. J Gastrointest Surg2006;10:1065. CrossRef

123. ShararaAI, AzarC, AmrSS, et al.Solitary rectal ulcer syndrome: endoscopic spectrum and review of the literature. Gastrointest Endosc2005;62:755. CrossRef

124. SinghB, MortensenNJ, WarrenBF. Histopathological mimicry in mucosal prolapse. Histopathology2007;50:97. CrossRef

125. HouJK, LeeD, LewisJ. Diet and inflammatory bowel disease: review of patient‐targeted recommendations. Clin Gastroenterol Hepatol2014;12:1592. CrossRef

126. GrahamTO, KandilHM. Nutritional factors in inflammatory bowel disease. Gastroenterol Clin North Am2002;31:203. CrossRef

127. DickinsonRJ, AshtonMG, AxonAT, et al.Controlled trial of intravenous hyperalimentation and total bowel rest as an adjunct to the routine therapy of acute colitis. Gastroenterology1980;79:1199.

128. JarnerotG, RolnyP, Sandberg‐GertzenH. Intensive intravenous treatment of ulcerative colitis. Gastroenterology1985;89:1005.

129. StensonWF, CortD, RodgersJ, et al.Dietary supplementation with fish oil in ulcerative colitis. Ann Intern Med1992;116:609. CrossRef

130. KlotzU, MaierK, FischerC, et al.Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease. N Engl J Med1980;303:1499. CrossRef

131. GisbertJP, GomollonF, MateJ, et al.Role of 5‐aminosalicylic acid (5‐ASA) in treatment of inflammatory bowel disease: a systematic review. Dig Dis Sci2002;47:471. CrossRef

132. van BodegravenAA, MulderCJ. Indications for 5‐aminosalicylate in inflammatory bowel disease: is the body of evidence complete?World J Gastroenterol2006;12:6115.

133. GreenfieldSM, PunchardNA, TeareJP, et al.Review article: the mode of action of the aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther1993;7:369. CrossRef

134. SandbornWJ, HanauerSB. The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro‐drugs used in the management of ulcerative colitis. Aliment Pharmacol Ther2003;17:29. CrossRef

135. Azad KhanAK, PirisJ, TrueloveSC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet1977;2:892.

136. DesreumauxP, GhoshS. Review article: mode of action and delivery of 5‐aminosalicylic acid – new evidence. Aliment Pharmacol Ther2006;24(Suppl 1):2. CrossRef

137. AllgayerH. Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther2003;18(Suppl 2):10. CrossRef

138. NikolausS, FolscnU, SchreiberS. Immunopharmacology of 5‐aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology2000;47:71.

139. WahlC, LiptayS, AdlerG, et al.Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest1998;101:1163. CrossRef

140. WalkerAM, SznekeP, BianchiLA, et al.5‐Aminosalicylates, sulfasalazine, steroid use, and complications in patients with ulcerative colitis. Am J Gastroenterol1997;92:816.

141. WadaK, NakajimaA, BlumbergRS. PPARgamma and inflammatory bowel disease: a new therapeutic target for ulcerative colitis and Crohn's disease. Trends Mol Med2001;7:329. CrossRef

142. KlotzU. Colonic targeting of aminosalicylates for the treatment of ulcerative colitis. Dig Liver Dis2005;37:381. CrossRef

143. RachmilewitzD, SharonP, LigumskyM, et al.Mechanism of sulphasalazine action in ulcerative colitis. Lancet1978;2:946. CrossRef

144. ParrySD, BarbatzasC, PeelET, et al.Sulphasalazine and lung toxicity. Eur Respir J2002;19:756. CrossRef

145. JansenG, van der HeijdenJ, OerlemansR, et al.Sulfasalazine is a potent inhibitor of the reduced folate carrier: implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum2004;50:2130. CrossRef

146. LowryPW, FranklinCL, WeaverAL, et al.Leucopenia resulting from a drug interaction between azathioprine or 6‐mercaptopurine and mesalamine, sulphasalazine, or balsalazide. Gut2001;49:656. CrossRef

147. TeefyAM, MartinJE, KovacsMJ. Warfarin resistance due to sulfasalazine. Ann Pharmacother2000;34:1265. CrossRef

148. HanauerSB. Review article: aminosalicylates in inflammatory bowel disease. Aliment Pharmacol Ther2004;20(Suppl 4):60. CrossRef

149. CampieriM, LanfranchiGA, BazzocchiG, et al.Treatment of ulcerative colitis with high‐dose 5‐aminosalicylic acid enemas. Lancet1981;2:270. CrossRef

150. HanauerSB. Review articles: drug therapy: inflammatory bowel disease. N Engl J Med1996;334:841. CrossRef

151. KlesKA, VavrickaSR, TurnerJR, et al.Comparative analysis of the in vitro prosecretory effects of balsalazide, sulfasalazine, olsalazine, and mesalamine in rabbit distal ileum. Inflamm Bowel Dis2005;11:253. CrossRef

152. QureshiAI, CohenRD. Mesalamine delivery systems: do they really make much difference?Adv Drug Deliv Rev2005;57:281. CrossRef

153. FarrellRJ, PeppercornMA. Equimolar doses of balsalazide and mesalamine: are we comparing apples and oranges?Am J Gastroenterol2002;97:1283. CrossRef

154. LichtensteinGR, KammMA, BodduP, et al.Effect of once‐ or twice‐daily MMX Mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol2007;5:95. CrossRef

155. WadworthAN, FittonA. Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease. Drugs1991;41:647. CrossRef

156. RagunathK, WilliamsJG. Review article: balsalazide therapy in ulcerative colitis. Aliment Pharmacol Ther2001;15:1549. CrossRef

157. SandbornWJ. Treatment of ulcerative colitis with oral mesalamine: advances in drug formulation, efficacy expectations and dose response, compliance, and chemoprevention. Rev Gastroenterol Disord2006;6:97.

158. HanauerSB, SandbornWJ, KornbluthA, et al.Delayed‐release oral mesalamine at 4.8 g/day (800 mg tablet) for the treatment of moderately active ulcerative colitis: the ASCEND II trial. Am J Gastroenterol2005;100:2478. CrossRef

159. SossaiP, CappellatoMG, StefaniS. Can a drug‐induced pulmonary hypersensitivity reaction be dose‐dependent? A case with mesalamine. [Review] [29 refs]. Mt Sinai J Med2001;68:389.

160. TrisoliniR, DoreR, BiagiF, et al.Eosinophilic pleural effusion due to mesalamine. Report of a rare occurrence. Sarcoidosis Vas Diffuse Lung Dis2000;17:288.

161. BakerDE, KaneS. The short‐ and long‐term safety of 5‐aminosalicylate products in the treatment of ulcerative colitis. Rev Gastroenterol Disord2004;4:86.

162. DeB, StolearJC, NouwenEJ, et al.5‐Aminosalicylic acid (5‐ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?. [Review] [10 refs]. Nephrol Dial Transplant1997;12:1839. CrossRef

163. CorriganG, StevensPE. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther2000;14:1. CrossRef

164. BergmanR, ParkesM. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther2006;23:841. CrossRef

165. GionchettiP, RizzelloF, VenturiA, et al.Comparison of oral with rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum1998;41:93. CrossRef

166. MarteauP, ProbertCS, LindgrenS, et al.Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study. Gut2005;54:960. CrossRef

167. KammMA, SandbornWJ, GassullM, et al.Once‐daily, high‐concentration MMX Mesalamine in active ulcerative colitis. Gastroenterology2007;132:66. CrossRef

168. MuijsersRB, GoaKL. Balsalazide: a review of its therapeutic use in mild‐to‐moderate ulcerative colitis. Drugs2002;62:1689. CrossRef

169. PrakashA, SpencerCM. Balsalazide. Drugs1998;56:83. CrossRef

170. d′AlbasioG, PaciniF, CamarriE, et al.Combined therapy with 5‐aminosalicylic acid tablets and enemas for maintaining remission in ulcerative colitis: a randomized double‐blind study. Am J Gastroenterol1997;92:1143.

171. KlotzU. The role of aminosalicylates at the beginning of the new millennium in the treatment of chronic inflammatory bowel disease. [Review] [137 refs]. Eur J Clin Pharmacol2000;56:353. CrossRef

172. SutherlandL, MacdonaldJK. Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev (Online)2006;CD000544.

173. SutherlandL, RothD, BeckP, et al.The Use of Oral 5‐Aminosalicylic Acid for Maintenance of Remission in Ulcerative Colitis (Cochrane Review). Oxford: Update Software; 1998.

174. BurkeDA, AxonAT, ClaydenSA, et al.The efficacy of tobramycin in the treatment of ulcerative colitis. Aliment Pharmacol Ther1990;4:123. CrossRef

175. MantzarisGJ, HatzisA, KontogiannisP, et al.Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol1994;89:43.

176. TurunenUM, FarkkilaMA, HakalaK, et al.Long‐term treatment of ulcerative colitis with ciprofloxacin: a prospective, double‐blind, placebo‐controlled study. Gastroenterology1998;115:1072. CrossRef

177. ChapmanRW, SelbyWS, JewellDP. Controlled trial of intravenous metronidazole as an adjunct to corticosteroids in severe ulcerative colitis. Gut1986;27:1210. CrossRef

178. MinerJ, GillanMM, AlexP, et al.Steroid‐refractory ulcerative colitis treated with corticosteroids, metronidazole and vancomycin: a case report. BMC Gastroenterol2005;5:3. CrossRef

179. GardnerME. Use of vancomycin in treating ulcerative colitis. Am J Hosp Pharm1981;38:473.

180. RahimiR, NikfarS, RezaieA, et al.A meta‐analysis of antibiotic therapy for active ulcerative colitis. Dig Dis Sci2007;52:2920. CrossRef

181. GionchettiP, RizzelloF, FerrieriA, et al.Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid‐treatment: a double‐blind, placebo‐controlled trial. Dig Dis Sci1999;44:1220. CrossRef

182. MimuraT, RizzelloF, HelwigU, et al.Four‐week open‐label trial of metronidazole and ciprofloxacin for the treatment of recurrent or refractory pouchitis. Aliment Pharmacol Ther2002;16:909. CrossRef

183. PardiDS, SandbornWJ. Systematic review: the management of pouchitis. Aliment Pharmacol Ther2006;23:1087. CrossRef

184. GionchettiP, RizzelloF, VenturiA, et al.Review – antibiotic treatment in inflammatory bowel disease: rifaximin, a new possible approach. Eur Rev Med Pharmacol Sci1999;3:27.

185. IsaacsKL, SandlerRS, AbreuM, et al.Rifaximin for the treatment of active pouchitis: a randomized, double‐blind, placebo‐controlled pilot study. Inflamm Bowel Dis2007;13:1250. CrossRef

186. AbdelrazeqAS, KellySM, LundJN, et al.Rifaximin‐ciprofloxacin combination therapy is effective in chronic active refractory pouchitis. Colorectal Dis2005;7:182. CrossRef

187. ShenB, FazioVW, RemziFH, et al.Combined ciprofloxacin and tinidazole therapy in the treatment of chronic refractory pouchitis. Dis Colon Rectum2007;50:498. CrossRef

188. MimuraT, RizzelloF, HelwigU, et al.Once daily high dose probiotic therapy (VSL#3) for maintaining remission in recurrent or refractory pouchitis. Gut2004;53:108. CrossRef

189. GionchettiP, RizzelloF, HelwigU, et al.Prophylaxis of pouchitis onset with probiotic therapy: a double‐blind, placebo‐controlled trial. Gastroenterology2003;124:1202. CrossRef

190. GionchettiP, RizzelloF, VenturiA, et al.Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double‐blind, placebo‐controlled trial. Gastroenterology2000;119:305. CrossRef

191. LichtensteinGR, AbreuMT, CohenR, et al.American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology2006;130:940. CrossRef

192. BarnesPJ. Molecular mechanisms and cellular effects of glucocorticosteroids. Immunol Allergy Clin North Am2005;25:451. CrossRef

193. KatzJA. Treatment of inflammatory bowel disease with corticosteroids. Gastroenterol Clin North Am2004;33:171, vii. CrossRef

194. SchaafMJ, CidlowskiJA. Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol2002;83:37. CrossRef

195. ScholmerichJ. Review article: systemic and topical steroids in inflammatory bowel disease. Aliment Pharmacol Ther2004;20(Suppl 4):66. CrossRef

196. EdsbackerS, AnderssonT. Pharmacokinetics of budesonide (Entocort EC) capsules for Crohn's disease. Clin Pharmacokinet2004;43:803. CrossRef

197. TravisSP, DaneseS, KupcinskasL, et al.Once‐daily budesonide MMX in active, mild‐to‐moderate ulcerative colitis: results from the randomised CORE II study. Gut2014;63:433. CrossRef

198. CreedTJ, ProbertCS. Review article: steroid resistance in inflammatory bowel disease – mechanisms and therapeutic strategies. Aliment Pharmacol Ther2007;25:111. CrossRef

199. FarrellRJ, KelleherD. Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol2003;178:339. CrossRef

200. HondaM, OriiF, AyabeT, et al.Expression of glucocorticoid receptor beta in lymphocytes of patients with glucocorticoid‐resistant ulcerative colitis. Gastroenterology2000;118:859. CrossRef

201. OriiF, AshidaT, NomuraM, et al.Quantitative analysis for human glucocorticoid receptor alpha/beta mRNA in IBD. Biochem Biophys Res Commun2002;296:1286. CrossRef

202. KlingensteinG, LevyRN, KornbluthA, et al.Inflammatory bowel disease related osteonecrosis: report of a large series with a review of the literature. Aliment Pharmacol Ther2005;21:243. CrossRef

203. FreemanHJ, FreemanKJ. Prevalence rates and an evaluation of reported risk factors for osteonecrosis (avascular necrosis) in Crohn's disease. Can J Gastroenterol2000;14:138.

204. LichtensteinGR, SandsBE, PazianasM. Prevention and treatment of osteoporosis in inflammatory bowel disease. Inflamm Bowel Dis2006;12:797. CrossRef

205. SchoonEJ, BollaniS, MillsPR, et al.Bone mineral density in relation to efficacy and side effects of budesonide and prednisolone in Crohn's disease. Clin Gastroenterol Hepatol2005;3:113. CrossRef

206. MelekJ, SakurabaA. Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta‐analysis and systematic review. Clin Gastroenterol Hepatol2014;12:32. CrossRef

207. KaneSV, SchoenfeldP, SandbornWJ, et al.The effectiveness of budesonide therapy for Crohn's disease. Aliment Pharmacol Ther2002;16:1509. CrossRef

208. LichtensteinGR, AbreuMT, CohenR, et al.American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology2006;130:935. CrossRef

209. BaronJH, ConnellAM, KanaghinisTG, et al.Out‐patient treatment of ulcerative colitis. Comparison between three doses of oral prednisone. Br Med J1962;2:441. CrossRef

210. Powell‐TuckJ, BownRL, Lennard‐JonesJE. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol1978;13:833. CrossRef

211. HanauerSB. Medical therapy for ulcerative colitis 2004. Gastroenterology2004;126:1582. CrossRef

212. D′HaensG, SandbornWJ, FeaganBG, et al.A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007;132:763. CrossRef

213. Lennard‐JonesJE, MisiewiczJJ, ConnellAM, et al.Prednisone as maintenance treatment for ulcerative colitis in remission. Lancet1965;191:188. CrossRef

214. TrueloveSC, WittsLJ. Cortisone and corticotrophin in ulcerative colitis. Br Med J1959;1:387. CrossRef

215. Powell‐TuckJ, BownRL, ChambersTJ, et al.A controlled trial of alternate day prednisolone as a maintenance treatment for ulcerative colitis in remission. Digestion1981;22:263. CrossRef

216. WatkinsonG. Treatment of ulcerative colitis with topical hydrocortisone hemisuccinate sodium; a controlled trial employing restricted sequential analysis. Br Med J1958;2:1077. CrossRef

217. MarshallJK, IrvineEJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: a meta‐analysis. Gut1997;40:775. CrossRef

218. HamedaniR, FeldmanRD, FeaganBG. Review article: drug development in inflammatory bowel disease: budesonide–a model of targeted therapy. [Review] [49 refs]. Aliment Pharmacol Ther1997;11(Suppl 3):98. CrossRef

219. HalvorsenS, MyrenJ, AakvaagA. On the absorption of prednisone and prednisolone disodium phosphate after rectal administration. Scand J Gastroenterol1969;4:582.

220. BebbJR, ScottBB. How effective are the usual treatments for ulcerative colitis?Aliment Pharmacol Ther2004;20:143. CrossRef

221. CohenRD, WosethDM, ThistedRA, et al.A meta‐analysis and overview of the literature on treatment options for left‐sided ulcerative colitis and ulcerative proctitis. Am J Gastroenterol2000;95:1263. CrossRef

222. CampieriM, CottoneM, MiglioF, et al.Beclomethasone dipropionate enemas versus prednisolone sodium phosphate enemas in the treatment of distal ulcerative colitis. Aliment Pharmacol Ther1998;12:361. CrossRef

223. MeyersS, SacharDB, GoldbergJD, et al.Corticotropin versus hydrocortisone in the intravenous treatment of ulcerative colitis. A prospective, randomized, double‐blind clinical trial. Gastroenterology1983;85:351.

224. RosenbergW, IrelandA, JewellDP. High‐dose methylprednisolone in the treatment of active ulcerative colitis. J Clin Gastroenterol1990;12:40. CrossRef

225. BossaF, FiorellaS, CarusoN, et al.Continuous infusion versus bolus administration of steroids in severe attacks of ulcerative colitis: a randomized, double‐blind trial. Am J Gastroenterol2007;102:601. CrossRef

226. LennardL. The clinical pharmacology of 6‐mercaptopurine. Eur J Clin Pharmacol1992;43:329. CrossRef

227. SzawlowskiPW, Al‐SafiSA, DooleyT, et al.Azathioprine suppresses the mixed lymphocyte reaction of patients with Lesch‐Nyhan syndrome. Br J Clin Pharmacol1985;20:489. CrossRef

228. CampbellAC, SkinnerJM, HerseyP, et al.Immunosuppression in the treatment of inflammatory bowel disease. I. Changes in lymphoid sub‐populations in the blood and rectal mucosa following cessation of treatment with azathioprine. Clin Exp Immunol1974;16:521.

229. CampbellAC, SkinnerJM, MaclennanIC, et al.Immunosuppression in the treatment of inflammatory bowel disease. II. The effects of azathioprine on lymphoid cell populations in a double blind trial in ulcerative colitis. Clin Exp Immunol1976;24:249.

230. ChanGL, ErdmannGR, GruberSA, et al.Azathioprine metabolism: pharmacokinetics of 6‐mercaptopurine, 6‐thiouric acid and 6‐thioguanine nucleotides in renal transplant patients. J Clin Pharmacol1990;30:358. CrossRef

231. WeinshilboumR. Methyltransferase pharmacogenetics. Pharmacol Ther1989;43:77. CrossRef

232. PriceRA, KeithRA, SpielmanRS, et al.Major gene polymorphism for human erythrocyte (RBC) thiol methyltransferase (TMT). Genet Epidemiol1989;6:651. CrossRef

233. LennardL, Van LoonJA, WeinshilboumRM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther1989;46:149. CrossRef

234. ColombelJF, FerrariN, DebuysereH, et al.Genotypic analysis of thiopurine S‐methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology2000;118:1025. CrossRef

235. DubinskyMC. Azathioprine, 6‐mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol2004;2:731. CrossRef

236. DubinskyMC. Monitoring of AZA/6‐MP treatment in children with IBD is necessary. Inflamm Bowel Dis2003;9:386, discussion 392‐3. CrossRef

237. HoentjenF, SeinenML, HanauerSB, et al.Safety and effectiveness of long‐term allopurinol‐thiopurine maintenance treatment in inflammatory bowel disease. Inflamm Bowel Dis2013;19:363. CrossRef

238. SparrowMP. Use of allopurinol to optimize thiopurine immunomodulator efficacy in inflammatory bowel disease. Gastroenterol Hepatol (N Y)2008;4:505.

239. SparrowMP, HandeSA, FriedmanS, et al.Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther2005;22:441. CrossRef

240. DubinskyMC, FeldmanEJ, AbreuMT, et al.Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6‐mercaptopurine or azathioprine. Am J Gastroenterol2003;98:1058. CrossRef

241. LouisE, BelaicheJ. Optimizing treatment with thioguanine derivatives in inflammatory bowel disease. Best Pract Res Clin Gastroenterol2003;17:37. CrossRef

242. TemlA, SchwabM, HarrerM, et al.A prospective, open‐label trial of 6‐thioguanine in patients with ulcerative or indeterminate colitis. Scand J Gastroenterol2005;40:1205. CrossRef

243. FerlitschA, TemlA, ReinischW, et al.6‐thioguanine associated nodular regenerative hyperplasia in patients with inflammatory bowel disease may induce portal hypertension. Am J Gastroenterol2007;102:2495. CrossRef

244. de BoerNK, ReinischW, TemlA, et al.6‐Thioguanine treatment in inflammatory bowel disease: a critical appraisal by a European 6‐TG working party. Digestion2006;73:25. CrossRef

245. TemlA, SchwabM, HommesDW, et al.A systematic survey evaluating 6‐thioguanine‐related hepatotoxicity in patients with inflammatory bowel disease. Wien Klin Wochenschr2007;119:519. CrossRef

246. AdlerDJ, KorelitzBI. The therapeutic efficacy of 6‐mercaptopurine in refractory ulcerative colitis. Am J Gastroenterol1990;85:717.

247. FraserAG, OrchardTR, JewellDP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut2002;50:485. CrossRef

248. Boulton‐JonesJR, PritchardK, MahmoudAA. The use of 6‐mercaptopurine in patients with inflammatory bowel disease after failure of azathioprine therapy. Aliment Pharmacol Ther2000;14:1561. CrossRef

249. MarionJF. Toxicity of 6‐mercaptopurine/azathioprine in patients with inflammatory bowel disease. Inflamm Bowel Dis1998;4:116. CrossRef

250. PresentDH, MeltzerSJ, KrumholzMP, et al.6‐Mercaptopurine in the management of inflammatory bowel disease: short‐ and long‐term toxicity. Ann Intern Med1989;111:641. CrossRef

251. RussmannS, ZimmermannA, KrahenbuhlS, et al.Veno‐occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol2001;13:287. CrossRef

252. SeidererJ, ZechCJ, DieboldJ, et al.Nodular regenerative hyperplasia: a reversible entity associated with azathioprine therapy. Eur J Gastroenterol Hepatol2006;18:553. CrossRef

253. KorelitzBI, FullerSR, WarmanJI, et al.Shingles during the course of treatment with 6‐mercaptopurine for inflammatory bowel disease. Am J Gastroenterol1999;94:424. CrossRef

254. FarrellRJ, AngY, KileenP, et al.Increased incidence of non‐Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut2000;47:514. CrossRef

255. DayharshGA, LoftusEVJr, SandbornWJ, et al.Epstein‐Barr virus‐positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6‐mercaptopurine. Gastroenterology2002;122:72. CrossRef

256. KorelitzBI, MirskyFJ, FleisherMR, et al.Malignant neoplasms subsequent to treatment of inflammatory bowel disease with 6‐mercaptopurine. Am J Gastroenterol1999;94:3248. CrossRef

257. JessT, Horvath‐PuhoE, FallingborgJ, et al.Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a danish population‐based cohort study. Am J Gastroenterol2013;108:1869. CrossRef

258. PasternakB, SvanstromH, SchmiegelowK, et al.Use of azathioprine and the risk of cancer in inflammatory bowel disease. Am J Epidemiol2013;177:1296. CrossRef

259. FraserAG, OrchardTR, RobinsonEM, et al.Long‐term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther2002;16:1225. CrossRef

260. DisantiW, RajapakseRO, KorelitzBI, et al.Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6‐mercaptopurine for inflammatory bowel disease. Clin Gastroenterol Hepatol2006;4:1025. CrossRef

261. MackeyAC, GreenL, LiangLC, et al.Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr2007;44:265. CrossRef

262. KotlyarDS, OstermanMT, DiamondRH, et al.A systematic review of factors that contribute to hepatosplenic T‐cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol2011;9:36. CrossRef

263. KotlyarDS, BlonskiW, DiamondRH, et al.Hepatosplenic T‐cell lymphoma in inflammatory bowel disease: a possible thiopurine‐induced chromosomal abnormality. Am J Gastroenterol2010;105:2299. CrossRef

264. JewellDP, TrueloveSC. Azathioprine in ulcerative colitis: final report on controlled therapeutic trial. Br Med J1974;4:627. CrossRef

265. PearsonDC, MayGR, FickGH, et al.Azathioprine and 6‐mercaptopurine in Crohn disease. A meta‐analysis. Ann Intern Med1995;123:132. CrossRef

266. SoodA, KaushalV, MidhaV, et al.The beneficial effect of azathioprine on maintenance of remission in severe ulcerative colitis. J Gastroenterol2002;37:270. CrossRef

267. TimmerA, McDonaldJW, MacdonaldJK. Azathioprine and 6‐mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev2007;CD000478.

268. HawthorneAB, LoganRF, HawkeyCJ, et al.Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ1992;305:20. CrossRef

269. SoodA, MidhaV, SoodN, et al.Role of azathioprine in severe ulcerative colitis: one‐year, placebo‐controlled, randomized trial. Indian J Gastroenterol2000;19:14.

270. CampbellS, GhoshS. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5‐aminosalicylate therapy. Eur J Gastroenterol Hepatol2001;13:1297. CrossRef

271. GeorgeJ, PresentDH, PouR, et al.The long‐term outcome of ulcerative colitis treated with 6‐mercaptopurine. Am J Gastroenterol1996;91:1711.

272. SandbornWJ. Azathioprine: state of the art in inflammatory bowel disease. Scand J Gastroenterol Suppl1998;225:92. CrossRef

273. MahadevanU, TremaineWJ, JohnsonT, et al.Intravenous azathioprine in severe ulcerative colitis: a pilot study. Am J Gastroenterol2000;95:3463. CrossRef

274. CohenRD, SteinR, HanauerSB. Intravenous cyclosporin in ulcerative colitis: a five‐year experience. Am J Gastroenterol1999;94:1587. CrossRef

275. ActisGC, BressoF, AstegianoM, et al.Safety and efficacy of azathioprine in the maintenance of ciclosporin‐induced remission of ulcerative colitis. Aliment Pharmacol Ther2001;15:1307. CrossRef

276. MiyoshiJ, MatsuokaK, InoueN, et al.Mucosal healing with oral tacrolimus is associated with favorable medium‐ and long‐term prognosis in steroid‐refractory/dependent ulcerative colitis patients. J Crohns Colitis2013;7:e609. CrossRef

277. HortonRC. Therapeutic progress–review XXXVII. Methotrexate–an immunomodulator with expanding indications. J Clin Pharm Ther1990;15:89. CrossRef

278. ThomasR, CarrollGJ. Reduction of leukocyte and interleukin‐1 beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum1993;36:1244. CrossRef

279. SeitzM, ZwickerM, LoetscherP. Effects of methotrexate on differentiation of monocytes and production of cytokine inhibitors by monocytes. Arthritis Rheum1998;41:2032. CrossRef

280. KozarekRA, PattersonDJ, GelfandMD, et al.Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med1989;110:353. CrossRef

281. EganLJ, SandbornWJ, MaysDC, et al.Systemic and intestinal pharmacokinetics of methotrexate in patients with inflammatory bowel disease. Clin Pharmacol Ther1999;65:29. CrossRef

282. DahlMG, GregoryMM, ScheuerPJ. Methotrexate hepatotoxicity in psoriasis–comparison of different dose regimens. Br Med J1972;1:654. CrossRef

283. TeHS, SchianoTD, KuanSF, et al.Hepatic effects of long‐term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol2000;95:3150. CrossRef

284. RichardS, GuerretS, GerardF, et al.Hepatic fibrosis in rheumatoid arthritis patients treated with methotrexate: application of a new semi‐quantitative scoring system. Rheumatology (Oxford)2000;39:50. CrossRef

285. ChandeN, MacDonaldJK, McDonaldJW. Methotrexate for induction of remission in ulcerative colitis. Cochrane Database Syst Rev2007;CD006618.

286. CummingsJR, HerrlingerKR, TravisSP, et al.Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther2005;21:385. CrossRef

287. FlanaganWM, CorthesyB, BramRJ, et al.Nuclear association of a T‐cell transcription factor blocked by FK‐506 and cyclosporin A. Nature1991;352:803. CrossRef

288. LangfordCA, KlippelJH, BalowJE, et al.Use of cytotoxic agents and cyclosporine in the treatment of autoimmune disease. Part 1: rheumatologic and renal diseases. Ann Intern Med1998;128:1021. CrossRef

289. ActisGC, AimoG, PrioloG, et al.Efficacy and efficiency of oral microemulsion cyclosporin versus intravenous and soft gelatin capsule cyclosporin in the treatment of severe steroid‐refractory ulcerative colitis: an open‐label retrospective trial. Inflamm Bowel Dis1998;4:276.

290. LichtigerS, PresentDH, KornbluthA, et al.Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med1994;330:1841. CrossRef

291. Van AsscheG, D′HaensG, NomanM, et al.Randomized, double‐blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology2003;125:1025. CrossRef

292. D′HaensG, LemmensL, GeboesK, et al.Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology2001;120:1323. CrossRef

293. KornbluthA, PresentDH, LichtigerS, et al.Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol1997;92:1424.

294. ScottLJ, McKeageK, KeamSJ, et al.Tacrolimus: a further update of its use in the management of organ transplantation. Drugs2003;63:1247. CrossRef

295. TegzessAM, DoorenbosBM, MinderhoudJM, et al.Prospective serial renal function studies in patients with nonrenal disease treated with cyclosporine A. Transplant Proc1988;20:530.

296. KobayashiT, NaganumaM, OkamotoS, et al.Rapid endoscopic improvement is important for 1‐year avoidance of colectomy but not for the long‐term prognosis in cyclosporine A treatment for ulcerative colitis. J Gastroenterol2010;45:1129. CrossRef

297. TreemWR, CohenJ, DavisPM, et al.Cyclosporine for the treatment of fulminant ulcerative colitis in children. Immediate response, long‐term results, and impact on surgery. Dis Colon Rectum1995;38:474. CrossRef

298. LoftusCG, EganLJ, SandbornWJ. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am2004;33:141, vii. CrossRef

299. PhamCQ, EfrosCB, BerardiRR. Cyclosporine for severe ulcerative colitis. Ann Pharmacother2006;40:96. CrossRef

300. SandbornWJ. Cyclosporine in ulcerative colitis: state of the art. Acta Gastroenterol Belg2001;64:201.

301. SoodA, MidhaV, SoodN. Oral cyclosporine in patients with active severe ulcerative colitis not responding to steroids. Indian J Gastroenterol2002;21:155.

302. OgataH, KatoJ, HiraiF, et al.Double‐blind, placebo‐controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid‐refractory ulcerative colitis. Inflamm Bowel Dis2012;18:803. CrossRef

303. OgataH, MatsuiT, NakamuraM, et al.A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut2006;55:1255. CrossRef

304. YamamotoS, NakaseH, MatsuuraM, et al.Tacrolimus therapy as an alternative to thiopurines for maintaining remission in patients with refractory ulcerative colitis. J Clin Gastroenterol2011;45:526. CrossRef

305. YamamotoS, NakaseH, MikamiS, et al.Long‐term effect of tacrolimus therapy in patients with refractory ulcerative colitis. Aliment Pharmacol Ther2008;28:589. CrossRef

306. VasiliauskasEA, KamLY, Abreu‐MartinMT, et al.An open‐label pilot study of low‐dose thalidomide in chronically active, steroid‐dependent Crohn's disease. Gastroenterology1999;117:1278. CrossRef

307. SandbornWJ, HanauerSB, KatzS, et al.Etanercept for active Crohn's disease: a randomized, double‐blind, placebo‐controlled trial. Gastroenterology2001;121:1088. CrossRef

308. FeaganBG, SandbornWJ, LichtensteinG, et al.CDP571, a humanized monoclonal antibody to tumour necrosis factor‐alpha, for steroid‐dependent Crohn's disease: a randomized, double‐blind, placebo‐controlled trial. Aliment Pharmacol Ther2006;23:617. CrossRef

309. SalvanaEM, CooperGS, SalataRA. Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab‐treated patients. J Infect2007;55:484. CrossRef

310. LeeJH, SlifmanNR, GershonSK, et al.Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum2002;46:2565. CrossRef

311. KeaneJ, GershonS, WiseRP, et al.Tuberculosis associated with infliximab, a tumor necrosis factor alpha‐neutralizing agent. N Engl J Med2001;345:1098. CrossRef

312. AndrisaniG, MarzoM, CellenoL, et al.Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab. Eur Rev Med Pharmacol Sci2013;17:2831.

313. FameniniS, WuJJ. Infliximab‐induced psoriasis in treatment of Crohn's disease‐associated ankylosing spondylitis: case report and review of 142 cases. J Drugs Dermatol2013;12:939.

314. GrattendickKJ, NakashimaJM, FengL, et al.Effects of three anti‐TNF‐alpha drugs: etanercept, infliximab and pirfenidone on release of TNF‐alpha in medium and TNF‐alpha associated with the cell in vitro. Int Immunopharmacol2008;8:679. CrossRef

315. ScallonBJ, MooreMA, TrinhH, et al.Chimeric anti‐TNF‐alpha monoclonal antibody cA2 binds recombinant transmembrane TNF‐alpha and activates immune effector functions. Cytokine1995;7:251. CrossRef

316. ReinischW, SandbornWJ, RutgeertsP, et al.Long‐term infliximab maintenance therapy for ulcerative colitis: the ACT‐1 and ‐2 extension studies. Inflamm Bowel Dis2012;18:201. CrossRef

317. RutgeertsP, SandbornWJ, FeaganBG, et al.Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med2005;353:2462. CrossRef

318. SandsBE, TremaineWJ, SandbornWJ, et al.Infliximab in the treatment of severe, steroid‐refractory ulcerative colitis: a pilot study. Inflamm Bowel Dis2001;7:83. CrossRef

319. ColombelJF, RutgeertsP, ReinischW, et al.Early mucosal healing with infliximab is associated with improved long‐term clinical outcomes in ulcerative colitis. Gastroenterology2011;141:1194. CrossRef

320. FeaganBG, RutgeertsP, SandsBE, et al.Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med2013;369:699. CrossRef

321. JarnerotG, HertervigE, Friis‐LibyI, et al.Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo‐controlled study. Gastroenterology2005;128:1805. CrossRef

322. LaharieD, BourreilleA, BrancheJ, et al.Cyclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open‐label randomised controlled trial. Lancet2012;380:1909. CrossRef

323. ChaparroM, BurguenoP, IglesiasE, et al.Infliximab salvage therapy after failure of ciclosporin in corticosteroid‐refractory ulcerative colitis: a multicentre study. Aliment Pharmacol Ther2012;35:275. CrossRef

324. MaserEA, DecondaD, LichtigerS, et al.Cyclosporine and infliximab as rescue therapy for each other in patients with steroid‐refractory ulcerative colitis. Clin Gastroenterol Hepatol2008;6:1112. CrossRef

325. BaertF, NomanM, VermeireS, et al.Influence of immunogenicity on the long‐term efficacy of infliximab in Crohn's disease. N Engl J Med2003;348:601. CrossRef

326. FarrellRJ, AlsahliM, JeenYT, et al.Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology2003;124:917. CrossRef

327. GisbertJP, Gonzalez‐LamaY, MateJ. Systematic review: infliximab therapy in ulcerative colitis. Aliment Pharmacol Ther2007;25:19. CrossRef

328. VermeireS, NomanM, van AsscheG, et al.The effectiviness of concomitant immunosuppressive therapy to suppress formation of antibodies to infliximab in crohn's disease. Gut2007;56:1226. CrossRef

329. Van AsscheG, Magdelaine‐BeuzelinC, D′HaensG, et al.Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology2008;134:1861. CrossRef

330. PanaccioneR, GhoshS, MiddletonS, et al.Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology2014;146:392. CrossRef

331. ColombelJF, LoftusEVJr, TremaineWJ, et al.The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology2004;126:19. CrossRef

332. BaertF, DrobneD, GilsA, et al.Early trough levels and antibodies to infliximab predict safety and success of reinitiation of infliximab therapy. Clin Gastroenterol Hepatol2014;12:1474. CrossRef

333. RuemmeleFM, LachauxA, CezardJP, et al.Efficacy of infliximab in pediatric Crohn's disease: a randomized multicenter open‐label trial comparing scheduled to on demand maintenance therapy. Inflamm Bowel Dis2009;15:388. CrossRef

334. LichtensteinGR, FeaganBG, CohenRD, et al.Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol2006;4:621. CrossRef

335. LichtensteinG, FeaganBG, CohenRD, et al.Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow‐up in the TREAT™ registry. Am J Gastroenterol2012;107:1409. doi: 10.1038/ajg.2012.218; [Epub 2012 Aug 14]. CrossRef

336. LichtensteinGR, FeaganBG, CohenRD, et al.Serious infection and mortality in patients with Crohn's disease: more than 5 years of follow‐up in the TREAT registry. Am J Gastroenterol2012;107:1409. CrossRef

337. BianconeL, CalabreseE, PetruzzielloC, et al.Treatment with biologic therapies and the risk of cancer in patients with IBD. Nat Clin Pract2007;4:78.

338. BernsteinCN, BlanchardJF, KliewerE, et al.Cancer risk in patients with inflammatory bowel disease: a population‐ based study. Cancer2001;91:854. CrossRef

339. HanauerS, LukasM, MacintoshD, et al.A randomized, double‐blind, placebo‐controlled trial of the human anti‐TNF‐alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active crohn's disease. Gastroenterology2004;127:332. CrossRef

340. ReinischW, SandbornWJ, HommesDW, et al.Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut2011;60:780. CrossRef

341. BurnessCB, KeatingGM. Adalimumab: a review of its use in the treatment of patients with ulcerative colitis. Biodrugs2013;27:247. CrossRef

342. SandbornWJ, van AsscheG, ReinischW, et al.Adalimumab induces and maintains clinical remission in patients with moderate‐to‐severe ulcerative colitis. Gastroenterology2012;142:257. CrossRef

343. SandbornWJ, FeaganBG, MaranoC, et al.Subcutaneous golimumab induces clinical response and remission in patients with moderate‐to‐severe ulcerative colitis. Gastroenterology2014;146:85. CrossRef

344. SandbornWJ, FeaganBG, MaranoC, et al.Subcutaneous golimumab maintains clinical response in patients with moderate‐to‐severe ulcerative colitis. Gastroenterology2014;146:96. CrossRef

345. TarganSR, FeaganBG, FedorakRN, et al.Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology2007;132:1672. CrossRef

346. SakurabaA, KeyashianK, CorreiaC, et al.Natalizumab in Crohn's disease: results from a US tertiary inflammatory bowel disease center. Inflamm Bowel Dis2013;19:621. CrossRef

347. DaneseS, PanésJ. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases. Gastroenterology2014;147:981. CrossRef

348. VermeireS, O′ByrneS, KeirM, et al.Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet2014;384:309. doi: 10.1016/S0140‐6736(14)60661‐9; [Epub 2014 May 9]. CrossRef

349. PanWJ, KöckK, ReesWA, et al.Clinical pharmacology of AMG 181, a gut‐specific human anti‐α4β7 monoclonal antibody, for treating inflammatory bowel diseases. Br J Clin Pharmacol2014;78:1315. doi: 10.1111/bcp.12418. CrossRef

350. VermeireS, GhoshS, PanesJ, et al.The mucosal addressin cell adhesion molecule antibody PF‐00547,659 in ulcerative colitis: a randomised study. Gut2011;60:1068. doi: 10.1136/gut.2010.226548; [Epub 2011 Feb 11]. CrossRef

351. SandbornWJ, GhoshS, PanesJ, et al.Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med2012;367:616. CrossRef

352. BurgerD, TravisS. Conventional medical management of inflammatory bowel disease. Gastroenterology2011;140:1827. CrossRef

353. RubinDT, HuoD, KinnucanJA, et al.Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a case‐control study. Clin Gastroenterol Hepatol2013;11:1601. CrossRef

354. RubinDT, LoSavioA, YadronN, et al.Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol2006;4:1346. CrossRef

355. BergAM, KellyCP, FarrayeFA. Clostridium difficile infection in the inflammatory bowel disease patient. Inflamm Bowel Dis2013;19:194. CrossRef

356. LarsonDW, PembertonJH. Current concepts and controversies in surgery for IBD. Gastroenterology2004;126:1611. CrossRef

357. NguyenGC, PratherCM. Is keeping the colon the ultimate marker of success in ulcerative colitis?Gastroenterology2009;137:1204. CrossRef

358. d′AlbasioG, PaoluziP, CampieriM, et al.Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double‐blind placebo‐controlled trial. The Italian IBD Study Group. Am J Gastroenterol1998;93:799. CrossRef

359. RegueiroM, LoftusEVJr, SteinhartAH, et al.Clinical guidelines for the medical management of left‐sided ulcerative colitis and ulcerative proctitis: summary statement. Inflamm Bowel Dis2006;12:972. CrossRef

360. BittonA. Medical management of ulcerative proctitis, proctosigmoiditis, and left‐sided colitis. Semin Gastrointest Dis2001;12:263.

361. LoftusEVJr, SandbornWJ. Epidemiology of inflammatory bowel disease. Gastroenterol Clin North Am2002;31:1. CrossRef

362. ArdizzoneS, PorroGB. Comparative tolerability of therapies for ulcerative colitis. Drug Saf2002;25:561. CrossRef

363. CriscuoliV, SinagraE, CottoneM. Budesonide MMX and mesalamine to induce remission in patients with ulcerative colitis. Gastroenterology2013;144:e23. CrossRef

364. SafdiM, DeMiccoM, SninskyC, et al.A double‐blind comparison of oral versus rectal mesalamine versus combination therapy in the treatment of distal ulcerative colitis. Am J Gastroenterol1997;92:1867.

365. HogenauerC, WenzlHH, HinterleitnerTA, et al.Effect of oral tacrolimus (FK 506) on steroid‐refractory moderate/severe ulcerative colitis. Aliment Pharmacol Ther2003;18:415. CrossRef

366. CaprilliR, ViscidoA, LatellaG. Current management of severe ulcerative colitis. Nat Clin Pract2007;4:92.

367. BianchiP. Medical Treatment of ulcerative colitis: overview. Eur J Gastroenterol Hepatol1997;9:827. CrossRef

368. NakaseH, YamamotoS, MatsuuraM, et al.Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus. Aliment Pharmacol Ther2010;32:510. CrossRef

369. SandbornWJ, RutgeertsP, FeaganBG, et al.Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab. Gastroenterology2009;137:1250. CrossRef

370. NaganumaM, SakurabaA, HibiT. Ulcerative colitis: prevention of relapse. Expert Rev Gastroenterol Hepatol2013;7:341. CrossRef

371. SutherlandL, RothD, BeckP, et al.Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev2002;CD000544.

372. ShethSG, LaMontJT. Toxic megacolon. Lancet1998;351:509. CrossRef

373. SteinR, HanauerSB. Life‐threatening complications of IBD: how to handle fulminant colitis and toxic megacolon. J Crit Illness1998;13:518.

374. GreensteinAJ, SacharDB, GibasA, et al.Outcome of toxic dilatation in ulcerative and Crohn's colitis. J Clin Gastroenterol1985;7:137. CrossRef

375. JalanKN, SircusW, CardWI, et al.An experience of ulcerative colitis. I. Toxic dilation in 55 cases. Gastroenterology1969;57:68.

376. GreensteinAJ, BarthJA, SacharDB, et al.Free colonic perforation without dilatation in ulcerative colitis. Am J Surg1986;152:272. CrossRef

377. AhmadM, NandiM, BannerjeeP, et al.Colonic perforation in ulcerative colitis. J Indian Med Assoc1977;68:52.

378. De DombalFT, WattsJM, WatkinsonG, et al.Local complications of ulcerative colitis: stricture, pseudopolyposis, and carcinoma of colon and rectum. Br Med J1966;1:1442. CrossRef

379. BonnevieO, BinderV, AnthonisenP, et al.The prognosis of ulcerative colitis. Scand J Gastroenterol1974;9:81.

380. RitchieJK, Powell‐TuckJ, Lennard‐JonesJE. Clinical outcome of the first ten years of ulcerative colitis and proctitis. Lancet1978;1:1140. CrossRef

381. SagarPM, PembertonJH. Update on the surgical management of ulcerative colitis and ulcerative proctitis: current controversies and problems. Inflamm Bowel Dis1995;1:299. CrossRef

382. BergerM, GribetzD, KorelitzBI. Growth retardation in children with ulcerative colitis: the effect of medical and surgical therapy. Pediatrics1975;55:459.

383. TelanderRL, SpencerM, PerraultJ, et al.Long‐term follow‐up of the ileoanal anastomosis in children and young adults. Surgery1990;108:717, discussion 723‐5.

384. FazioVW, KiranRP, RemziFH, et al.Ileal pouch anal anastomosis: analysis of outcome and quality of life in 3707 patients. Ann Surg2013;257:679. CrossRef

385. WuXR, MukewarS, HammelJP, et al.Comparable pouch retention rate between pediatric and adult patients after restorative proctocolectomy and ileal pouches. Clin Gastroenterol Hepatol2014;12:1295. CrossRef

386. WuB, LianL, LiY, et al.Clinical course of cuffitis in ulcerative colitis patients with restorative proctocolectomy and ileal pouch‐anal anastomoses. Inflamm Bowel Dis2013;19:404. CrossRef

387. FarrayeFA, OdzeRD, EadenJ, et al.AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology2010;138:738. CrossRef

388. FarrayeFA, OdzeRD, EadenJ, et al.AGA technical review on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology2010;138:746, 774.e1‐4. CrossRef

389. ItzkowitzS. Colon carcinogenesis in inflammatory bowel disease: applying molecular genetics to clinical practice. J Clin Gastroenterol2003;36:S70, discussion S94‐6. CrossRef

390. GreensteinAJ, SacharDB, PucilloA, et al.Cancer in universal and left‐sided ulcerative colitis: clinical and pathologic features. Mt Sinai J Med1979;46:25.

391. GreensteinAJ, SlaterG, HeimannTM, et al.A comparison of multiple synchronous colorectal cancer in ulcerative colitis, familial polyposis coli, and de novo cancer. Ann Surg1986;203:123. CrossRef

392. GreensteinAJ, SacharDB, SmithH, et al.Cancer in universal and left‐sided ulcerative colitis: factors determining risk. Gastroenterology1979;77:290.

393. EadenJA, MayberryJF. Colorectal cancer complicating ulcerative colitis: a review. Am J Gastroenterol2000;95:2710. CrossRef

394. JessT, RungoeC, Peyrin‐BirouletL. Risk of colorectal cancer in patients with ulcerative colitis: a meta‐analysis of population‐based cohort studies. Clin Gastroenterol Hepatol2012;10:639. CrossRef

395. WandersLK, DekkerE, PullensB, et al.Cancer risk after resection of polypoid dysplasia in patients with longstanding ulcerative colitis: a meta‐analysis. Clin Gastroenterol Hepatol2013;●●:●●.

396. JessT, LoftusEVJr, VelayosFS, et al.Risk of intestinal cancer in inflammatory bowel disease: a population‐based study from olmsted county, Minnesota. Gastroenterology2006;130:1039. CrossRef

397. AndersenNN, JessT. Has the risk of colorectal cancer in inflammatory bowel disease decreased?World J Gastroenterol2013;19:7561. CrossRef

398. ItzkowitzSH. Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol2004;287:G7. CrossRef

399. JayaramH, SatsangiJ, ChapmanRW. Increased colorectal neoplasia in chronic ulcerative colitis complicated by primary sclerosing cholangitis: fact or fiction?Gut2001;48:430. CrossRef

400. RubinDC, ShakerA, LevinMS. Chronic intestinal inflammation: inflammatory bowel disease and colitis‐associated colon cancer. Front Immunol2012;3:107. CrossRef

401. SinghS, VarayilJE, LoftusEVJr, et al.Incidence of colorectal cancer after liver transplantation for primary sclerosing cholangitis: a systematic review and meta‐analysis. Liver Transpl2013;19:1361. CrossRef

402. RubinDT, RotheJA, HetzelJT, et al.Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?Gastrointest Endosc2007;65:998. CrossRef

403. MorsonBC, PangLS. Rectal biopsy as an aid to cancer control in ulcerative colitis. Gut1967;8:423. CrossRef

404. DobbinsWO3rd.Current status of the precancer lesion in ulcerative colitis. Gastroenterology1977;73:1431.

405. UllmanT, CroogV, HarpazN, et al.Progression of flat low‐grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology2003;125:1311. CrossRef

406. DobbinsWO3rd, StockM, GinsbergAL. Early detection and prevention of carcinoma of the colon in patients with ulcerative colitis. Cancer1977;40:2542. CrossRef

407. EadenJ, AbramsK, McKayH, et al.Inter‐observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J Pathol2001;194:152. CrossRef

408. OdzeRD, GoldblumJ, NoffsingerA, et al.Interobserver variability in the diagnosis of ulcerative colitis‐associated dysplasia by telepathology. Mod Pathol2002;15:379. CrossRef

409. MpofuC, WatsonAJ, RhodesJM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev2004;CD000279.

410. CollinsPD, MpofuC, WatsonAJ, et al.Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev (Online)2006;CD000279.

411. ThomasT, AbramsKA, RobinsonRJ, et al.Meta‐analysis: cancer risk of low‐grade dysplasia in chronic ulcerative colitis. Aliment Pharmacol Ther2007;25:657. CrossRef

412. PekowJR, HetzelJT, RotheJA, et al.Outcome after surveillance of low‐grade and indefinite dysplasia in patients with ulcerative colitis. Inflamm Bowel Dis2010;16:1352. CrossRef

413. VelayosFS, LoftusEVJr, JessT, et al.Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case‐control study. Gastroenterology2006;130:1941. CrossRef

414. RutterMD, SaundersBP, WilkinsonKH, et al.Thirty‐year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology2006;130:1030. CrossRef

415. VelayosFS, TerdimanJP, WalshJM. Effect of 5‐aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol2005;100:1345. CrossRef

416. KorelitzBI. Inflammatory bowel disease and pregnancy. Gastroenterol Clin North Am1998;27:213. CrossRef

417. FriedmanS, RegueiroMD. Pregnancy and nursing in inflammatory bowel disease. Gastroenterol Clin North Am2002;31:265, xii. CrossRef

418. WilliamsonC. Drugs in pregnancy. Gastrointestinal disease. Best Pract Res Clin Obstet Gynaecol2001;15:937. CrossRef

419. TooveyS, HudsonE, HendryWF, et al.Sulphasalazine and male infertility: reversibility and possible mechanism. Gut1981;22:445. CrossRef

420. KornfeldD, CnattingiusS, EkbomA. Pregnancy outcomes in women with inflammatory bowel disease–a population‐based cohort study. Am J Obstet Gynecol1997;177:942. CrossRef

421. AlsteadE. Fertility and pregnancy in inflammatory bowel disease. World J Gastroenterol2001;7:455.

422. Ording OlsenK, JuulS, BerndtssonI, et al.Ulcerative colitis: female fecundity before diagnosis, during disease, and after surgery compared with a population sample. Gastroenterology2002;122:15. CrossRef

423. Ramsey‐GoldmanR, SchillingE. Immunosuppressive drug use during pregnancy. Rheum Dis Clin North Am1997;23:149. CrossRef

424. SubhaniJM, HamilitonMI. Review article: the management of inflammatory bowel disease during pregnancy. Aliment Pharmacol Ther1998;12:1039. CrossRef

425. MogadamM, DobbinsWO3rd, KorelitzBI, et al.Pregnancy in inflammatory bowel disease: effect of sulfasalazine and corticosteroids on fetal outcome. Gastroenterology1981;80:72.

426. KatzJA, PoreG. Inflammatory bowel disease and pregnancy. Inflamm Bowel Dis2001;7:146. CrossRef

427. GisbertJP. Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast‐feeding. Inflamm Bowel Dis2010;16:881. CrossRef

428. KatzJA, AntoniC, KeenanGF, et al.Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol2004;99:2385. CrossRef

429. SahaS, WaldA. Safety and efficacy of immunomodulators and biologics during pregnancy and lactation for the treatment of inflammatory bowel disease. Expert Opin Drug Saf2012;11:947. CrossRef

430. VasiliauskasEA, ChurchJA, SilvermanN, et al.Case report: evidence for transplacental transfer of maternally administered infliximab to the newborn. Clin Gastroenterol Hepatol2006;4:1255. CrossRef

431. HellerMM, WuJJ, MuraseJE. Fatal case of disseminated BCG infection after vaccination of an infant with in utero exposure to infliximab. J Am Acad Dermatol2011;65:870. CrossRef

432. MogadamM, KorelitzBI, AhmedSW, et al.The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol1981;75:265.

433. AuvinS, MolinieF, Gower‐RousseauC, et al.Incidence, clinical presentation and location at diagnosis of pediatric inflammatory bowel disease: a prospective population‐based study in northern France (1988–1999). J Pediatr Gastroenterol Nutr2005;41:49. CrossRef

434. KimSC, FerryGD. Inflammatory bowel diseases in pediatric and adolescent patients: clinical, therapeutic, and psychosocial considerations. Gastroenterology2004;126:1550. CrossRef

435. IssenmanRM. Bone mineral metabolism in pediatric inflammatory bowel disease. Inflamm Bowel Dis1999;5:192. CrossRef

436. OrloskiLA. Pediatric ulcerative colitis: a review of the disease and current therapy. Pediatr Nurs1998;24:165.

437. RiceHE, ChuangE. Current management of pediatric inflammatory bowel disease. Semin Pediatr Surg1999;8:221. CrossRef

438. JacobsteinDA, MamulaP, MarkowitzJE, et al.Predictors of immunomodulator use as early therapy in pediatric Crohn's disease. J Clin Gastroenterol2006;40:145. CrossRef

439. HyamsJ, DamarajuL, BlankM, et al.; T72 Study Group. Induction and maintenance therapy with infliximab for children with moderate to severe ulcerative colitis. Clin Gastroenterol Hepatol2012;10:391. doi: 10.1016/j.cgh.2011.11.026; [Epub 2011 Dec 8]. CrossRef

440. FonkalsrudEW. Surgery for pediatric ulcerative colitis. Curr Opin Pediatr1995;7:323. CrossRef